Literature DB >> 35000064

Anti-inflammatory cytokines in sickle cell disease.

Adekunle E Alagbe1, Igor F Domingos2, Adekunle D Adekile3, Maria H S L Blotta1, Magnun N N Santos4.   

Abstract

Sickle cell disease (SCD) is a well-studied monogenetic disease with an established chronic inflammatory component. The paradigm shift towards inflammation has made the pathophysiology of SCD even more complex. Studies have shown that an imbalance between the pro-inflammatory and anti-inflammatory cytokines in SCD exists; however, the reports are skewed toward the pro-inflammatory mediators. We enumerate recent in vitro and in vivo studies on anti-inflammatory cytokines in SCD patients, and discuss the biology of anti-inflammatory cytokines including the already reported IL-2, TGF-β, and IL-10 as well as the recently discovered IL-27, IL-35 and IL-37. This review will improve the understanding of the pathophysiology of SCD and aid in the search of new therapeutic options for patients with SCD.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Anti-inflammatory cytokines; Chronic inflammation; Pathophysiology; Sickle cell disease

Mesh:

Substances:

Year:  2022        PMID: 35000064     DOI: 10.1007/s11033-021-07009-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  95 in total

Review 1.  Pathophysiology of sickle cell disease: role of cellular and genetic modifiers.

Authors:  M H Steinberg; G P Rodgers
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

2.  Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia.

Authors:  Samir K Ballas; Mary Jane Marcolina
Journal:  Transfusion       Date:  2006-01       Impact factor: 3.157

Review 3.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 4.  Heme: Modulator of Plasma Systems in Hemolytic Diseases.

Authors:  Lubka T Roumenina; Julie Rayes; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  Trends Mol Med       Date:  2016-02-12       Impact factor: 11.951

5.  High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension.

Authors:  Nambirajan Sundaram; Anitaben Tailor; Laurel Mendelsohn; Janaka Wansapura; Xunde Wang; Tomoyasu Higashimoto; Michael W Pauciulo; William Gottliebson; Vijay K Kalra; William C Nichols; Gregory J Kato; Punam Malik
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

6.  Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs.

Authors:  Felicitas S Boretti; Paul W Buehler; Felice D'Agnillo; Katharina Kluge; Tony Glaus; Omer I Butt; Yiping Jia; Jeroen Goede; Claudia P Pereira; Marco Maggiorini; Gabriele Schoedon; Abdu I Alayash; Dominik J Schaer
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

Review 7.  Heme degradation and vascular injury.

Authors:  John D Belcher; Joan D Beckman; Gyorgy Balla; Jozsef Balla; Gregory Vercellotti
Journal:  Antioxid Redox Signal       Date:  2010-02       Impact factor: 8.401

Review 8.  Red alert: labile heme is an alarmin.

Authors:  Miguel P Soares; Marcelo T Bozza
Journal:  Curr Opin Immunol       Date:  2015-12-29       Impact factor: 7.486

Review 9.  Sickle cell disease: role of reactive oxygen and nitrogen metabolites.

Authors:  Katherine C Wood; D Neil Granger
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

10.  Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factor.

Authors:  Xunde Wang; Laurel Mendelsohn; Heather Rogers; Susan Leitman; Nalini Raghavachari; Yanqin Yang; Yu Ying Yau; Michael Tallack; Andrew Perkins; James G Taylor; Constance Tom Noguchi; Gregory J Kato
Journal:  Blood       Date:  2014-06-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.